JAK1 and neoplasm: Indeed, the defective TAP1 and LMP2 expression in these tumors is associated with a G871E mutation in the ATP-binding region of the JAK1 kinase domain, thereby affecting JAK1 kinase activity, but neither JAK1 expression nor its degradation [130] allow the tumor cells to evade anti-tumor specific immunity.